Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03665129 · ClinicalTrials.gov registry record · Phase 1
IPH5401 (Anti-C5aR) in Combination With Durvalumab in Patients With Advanced Solid Tumors
A Phase 1 study, sponsored by Innate Pharma.
- Terminated
- Registry status
- Phase 1
- Development phase
- 73
- Enrollment target
NCT03665129 is a Phase 1 study that was terminated before completion, run by Innate Pharma. The registered enrollment target is 73 participants.
The verdict
NCT03665129, a Phase 1 study, was terminated before completion, sponsored by Innate Pharma.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 73 participants
- Enrollment target
Study Summary
This is a multicenter, open-label, dose-escalation and dose-expansion study to evaluate the safety, tolerability, antitumor activity of IPH5401 (anti C5aR) in combination with Durvalumab (MEDI4736) in Adult Subjects with selected advanced solid tumors.
Interventions
- BIOLOGICAL IPH5401 and Durvalumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 73 participants |
| Start Date | 2018-09-07 |
| Est. Completion | 2021-02-24 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03665129
The ClinicalTrials.gov registry entry for NCT03665129 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 73 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Innate Pharma, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which IPH5401 and Durvalumab is the first listed.
NCT03665129 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03665129 about?
NCT03665129 is a clinical study titled "IPH5401 (Anti-C5aR) in Combination With Durvalumab in Patients With Advanced Solid Tumors". This is a multicenter, open-label, dose-escalation and dose-expansion study to evaluate the safety, tolerability, antitumor activity of IPH5401 (anti C5aR) in combination with Durvalumab (MEDI4736) in Adult Subjects with selected advanced solid tumors.
What is the current status of trial NCT03665129?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 73 participants. The study started on 2018-09-07. Estimated completion is 2021-02-24.
What interventions are being tested in trial NCT03665129?
The interventions under investigation include: IPH5401 and Durvalumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT03665129?
This trial is sponsored by Innate Pharma, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.